{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:38:42Z","timestamp":1791841122777,"version":"4.3.4"},"reference-count":28,"publisher":"Pensoft Publishers","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>Painless treatment is an integral element of quality pediatric dental care. Recent progress in the field of local anesthesia has led to development of newer agents, delivery devices and also modification in injection techniques. Their aim is to allow the clinician a treatment approach associated with the improved pain control and reduced risk of adverse effect essential for pediatric patients. This article reviews available information on current and alternative means, methods and technologies for achieving local anesthesia in pediatric patients intended to minimize the pain associated with the procedure.<\/jats:p>","DOI":"10.2478\/folmed-2018-0015","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T22:17:53Z","timestamp":1524089873000},"page":"381-388","source":"Crossref","is-referenced-by-count":10,"title":["Local Anesthesia in Pediatric Patients \u2013 a Review of Current and Alternative Methods, Devices and Techniques"],"prefix":"10.3897","volume":"60","author":[{"given":"Elitsa R.","family":"Veneva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ani B.","family":"Belcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2258","reference":[{"key":"ref171","first-page":"2013","article-title":"Estimating the budget impact of orphan drugs in Sweden","volume":"18","author":"Hutchings","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"ref191","first-page":"1031","article-title":"Cost - of - illness in rare diseases","volume":"20","author":"Linertov\u00e1","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10198-016-0780-7","article-title":"Social \/ economic costs and health - related quality of life in patients with rare diseases in Europe","volume":"21","author":"L\u00f3pez","year":"2016","journal-title":"Eur J Health Econ"},{"key":"ref121","article-title":"Pharmaceutical expenditure on drugs for rare diseases in a historical and prospective MIDAS sales data analysis","volume":"13","author":"Divino","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/COC.0000000000000251","article-title":"Fader AN The orphan drug act : restoring the mission to rare diseases","volume":"39","author":"Daniel","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"ref101","first-page":"2006","article-title":"Orphan drugs expenditure in the Netherlands in the period","volume":"11","author":"Kanters TA","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"ref331","first-page":"8","article-title":"Do health reforms impact cost consciousness of health care professionals ? Results from a nation - wide survey in the Balkans Balkan","volume":"33","author":"Jakovljevic","year":"2016","journal-title":"Med"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13023-016-0434-y","article-title":"Impact of orphan drugs on Latvian budget","volume":"14","author":"Logviss","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"ref21","first-page":"7","article-title":"Growth of global health spending share in low and middle income countries Front","author":"Jakovljevic","year":"2016","journal-title":"Pharmacol"},{"key":"ref51","article-title":"The new and old Europe West split in pharmaceutical spending Front","volume":"7","author":"Jakovljevic","year":"2016","journal-title":"East Pharmacol"},{"key":"ref81","first-page":"557","article-title":"Transposition and implementation of EU rare disease policy in Eastern Europe Expert Outcomes","volume":"17","author":"Pejcic","year":"2017","journal-title":"Rev Res"},{"key":"ref341","first-page":"181","article-title":"MB Contemporary generic market in Japan - key conditions to successful evolution Expert Outcomes","volume":"14","author":"Jakovljevic","year":"2014","journal-title":"Rev Res"},{"key":"ref111","article-title":"Orphan drug expenditures in the United States : a historical and prospective analysis","volume":"12","author":"Divino","year":"2007","journal-title":"Health"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jcpt.12006","article-title":"Dooms Do we need authorized orphan drugs when compounded medications are available","volume":"38","author":"Pinc\u00e9","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"ref151","first-page":"2015","article-title":"Budget impact analysis of drugs for ultra - orphan nononcological diseases in Europe Expert Pharmacoecon Outcomes","volume":"16","author":"Schlander","journal-title":"Rev Res"},{"key":"ref01","first-page":"1","article-title":"OECD expenditure by type of service In OECD at a Glance OECD Indicators Paris OECD Publishing","year":"2017","journal-title":"Health Health"},{"key":"ref221","first-page":"153","article-title":"Kesselheim AS Ethical considerations in orphan drug approval and use","volume":"23","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11606-014-2882-1","article-title":"Orphan therapies making best use of postmarket data","volume":"29","author":"Maro","year":"2014","journal-title":"J Gen Intern Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hec.3406","article-title":"Evolving health expenditure landscape of the BRICS nations and projections to","volume":"26","author":"Jakovljevic","year":"2025","journal-title":"Health Econ"},{"key":"ref271","first-page":"10","article-title":"The development of the Romanian Scorecard HTA system Value Health Reg Issues","volume":"28","author":"Radu","year":"2016","journal-title":"AM"},{"key":"ref181","first-page":"252","article-title":"economic data in reimbursement of new medical technologies : importance of the socioeconomic burden as a decision - making criterion Front","volume":"19","author":"Iskrov","year":"2016","journal-title":"Health Pharmacol"},{"key":"ref211","first-page":"2015","article-title":"burden and health - related quality of life of patients with cystic fibrosis in Bulgaria","volume":"22","author":"Iskrov","journal-title":"Economic Med"},{"key":"ref241","first-page":"359","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency : retrospective cohort study of drug approvals","volume":"25","author":"Davis","year":"2009"},{"key":"ref61","first-page":"2015","article-title":"Prospects of risk - sharing agreements for innovative therapies in a context of deficit spending in Bulgaria Front","author":"Iskrov","journal-title":"Public Health"},{"key":"ref231","first-page":"1","article-title":"Post - marketing access to orphan drugs : a critical analysis of health technology assessment and reimbursement decision - making considerations Orphan","volume":"24","author":"Iskrov","year":"2014","journal-title":"Drugs Res Rev"},{"key":"ref291","first-page":"390","article-title":"The The balancing act of orphan drug pricing","volume":"30","year":"2017","journal-title":"Lancet Lancet"},{"key":"ref141","article-title":"Budgetary impact and cost drivers of drugs for rare and ultrarare diseases Value Nov","volume":"15","author":"Schlander","year":"2017","journal-title":"Health"},{"key":"ref11","first-page":"1995","article-title":"Global Burden of Disease Health Financing Collaborator Network and patterns of global health financing development assistance for health and government prepaid private and out - of - pocket health spending in countries","author":"Dieleman","year":"2017","journal-title":"Evolution Lancet"}],"container-title":["Folia Medica"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/folmed.2018.60.issue-3\/folmed-2018-0015\/folmed-2018-0015.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.degruyter.com\/view\/j\/folmed.2018.60.issue-3\/folmed-2018-0015\/folmed-2018-0015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T18:36:38Z","timestamp":1565807798000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.degruyter.com\/view\/j\/folmed.2018.60.issue-3\/folmed-2018-0015\/folmed-2018-0015.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":28,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.2478\/folmed-2018-0015","relation":{},"ISSN":["1314-2143"],"issn-type":[{"value":"1314-2143","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}